References
- National Cholesterol Education Program , National Heart, Lung and Blood Institute, NIH . Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. NIH Publication No. 02-5215 . www.nhlbi.nih.gov ( 2002 ).
- WHO . Leading causes of death . www.who.int
- Stone NJ , RobinsonJ, LichtensteinAHet al. Cardiovascular risk in adults: a report of the American College of Cardiology/American 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Circulation129 ( 25 Suppl. 2 ), S1 – S45 ( 2014 ).
- Anderson TJ , GregoireJ, HegeleRAet al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult . Can. J. Cardiol.29 ( 2 ), 151 – 167 ( 2013 ).
- Catapano AL , ReinerZ, De BackerGet al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) . Atherosclerosis217 ( 1 ), 3 – 46 ( 2011 ).
- Waters DD , BrotonsC, ChiangCWet al. ; Lipid Treatment Assessment Project 2 Investigators . Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals . Circulation120, 28 – 34 ( 2009 ).
- Nordestgaard BG , ChapmanMJ, HumphriesSEet al. ; European Atherosclerosis Society Consensus Panel . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society . Eur. Heart J.34 ( 45 ), 3478a – 3490a ( 2013 ).
- Bruckert E , HayemG, DejagerS, YauC, BégaudB . Mild to moderatemuscular symptomswith high-dosage statin therapy in hyperlipidemic patients-the PRIMO study . Cardiovasc. Drugs Ther.19, 403 – 414 ( 2005 ).
- Abifadel M , VarretM, RabesJPet al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia . Nat. Genet.34, 154 – 6 ( 2003 ).
- Cohen JC , BoerwinkleE, MosleyTHJr, HobbsHH . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease . N. Engl. J. Med.354, 1264 – 72 ( 2006 ).
- Goldstein JL , BrownMS . The LDL receptor . Arterioscler. Thromb. Vasc. Biol.29, 431 – 438 ( 2009 ).
- Stein EA , SwergoldGD . Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics . Curr. Atheroscler. Rep.15, 310 ( 2013 ).
- Stein EA , MellisS, YancopoulosGDet al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol . N. Engl. J. Med.366, 1108 – 1118 ( 2012 ).
- McKenney JM , KorenMJ, KereiakesDJet al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy . J. Am. Coll. Cardiol.59, 2344 – 2353 ( 2012 ).
- Roth EM , McKenneyJM, HanotinC, AssetG, SteinEA . Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia . N. Engl. J. Med.367, 1891 – 1900 ( 2012 ).
- Roth EM , DillerP . Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody . Future Cardiol.10 ( 2 ), 183 – 99 ( 2014 ).
- Pordy R , LecropsG, BessacL, SasielaWG, GinsbergH . Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic dosing in Phase 3 studies . J. Clin. Lipidol.7, 279 ( 2013 ).
- Roth EM , TaskinenMR, GinsbergHNet al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial . Int. J. Cardiol.176 ( 1 ), 55 – 61 ( 2014 ).
- Conroy RM , PyoralaK, FitzgeraldAPet al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project . Eur. Heart J.24 ( 11 ), 987 – 1003 ( 2003 ).
- Bays HE , NeffD, TomassiniJE, TershakovecAM . Ezetimibe: cholesterol lowering and beyond . Expert Rev. Cardiovasc. Ther.6 ( 4 ), 447 – 470 ( 2008 ).
- Dubuc GA , ChamberlandH, WassefJet al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia . Arterioscler. Thromb. Vasc. Biol.24, 1454 – 1459 ( 2004 ).